Lilly cuts a $960m deal with Rigel on RIP kinase

Eli Lilly has become the latest drugmaker to have a go at developing RIP kinase inhibitors, a new class of drugs with potential in autoimmune and inflammatory disease, paying $125 million u

Three strategies for managing loss of exclusivity successful...

FDA grants emergency licence for Lilly's COVID-19 antibody c...

The FDA has granted an emergency licence for Eli Lilly’s COVID-19 antibody combination therapy, to reduce chances of high-risk patients progressing from mild to moderate disease to more sev

Lilly adds to pain pipeline with Asahi Kasei licensing deal

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up t

Regeneron and Lilly post new data backing COVID antibody coc...

Regeneron is considering an emergency filing for its antibody cocktail REGEN-COV to protect people against COVID-19 after early trial results showed it conferred 100% protection against sym

Lilly bolts on cancer bispecifics with $1.6bn Merus alliance

Always a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes to cancer immunotherapy, but a new R&D alliance with Dutch biotech Merus is further evidenc